


# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

|                   |                                                   |
|-------------------|---------------------------------------------------|
| USAN (HI-144)     | RILZABRUTINIB                                     |
| PRONUNCIATION     | ril" za broo' ti nib                              |
| THERAPEUTIC CLAIM | Treatment of autoimmune and inflammatory diseases |
| CHEMICAL NAMES    |                                                   |

- 1-Piperidinepropanenitrile, 3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl]- $\alpha$ -[2-methyl-2-[4-(3-oxetanyl)-1-piperazinyl]propylidene]- $\beta$ -oxo-, (3*R*)-
2. (4*E*,7<sup>3</sup>*R*)-8<sup>4</sup>-amino-9<sup>2</sup>-fluoro-3,3-dimethyl-6-oxo-10-oxa-8(1,3)-pyrazolo[3,4-*d*]pyrimidina-2(1,4) piperazina-7(1,3)-piperidina-1(3)-oxetana-9(1,4),11(1)-dibenzenaundecaphan-4-ene-5 carbonitrile

## STRUCTURAL FORMULA



|                            |                                                                |
|----------------------------|----------------------------------------------------------------|
| MOLECULAR FORMULA          | C <sub>36</sub> H <sub>40</sub> FN <sub>9</sub> O <sub>3</sub> |
| MOLECULAR WEIGHT           | 665.8                                                          |
| TRADEMARK                  | None as yet                                                    |
| SPONSOR                    | Principia Biopharma Inc.                                       |
| CODE DESIGNATIONS          | PRN1008                                                        |
| <u>CAS</u> REGISTRY NUMBER | 1575591-66-0                                                   |
| UNII                       | NWN58M4F5T                                                     |
| WHO NUMBER                 | 10966                                                          |

## SCS